{"id":"bemnifosbuvir-ruzasvir","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a fixed-dose combination targeting two distinct steps of the HCV replication cycle. Bemnifosbuvir acts as a chain terminator in viral RNA synthesis by inhibiting the NS5B polymerase, while ruzasvir prevents the proper functioning of the NS5A protein, which is essential for viral replication and assembly. Together, they provide complementary antiviral activity against HCV.","oneSentence":"Bemnifosbuvir is a nucleoside analog that inhibits hepatitis C virus (HCV) RNA-dependent RNA polymerase, while ruzasvir is an NS5A inhibitor that blocks viral protein function and replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:02.347Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, genotype 1-6"}]},"trialDetails":[{"nctId":"NCT07037277","phase":"PHASE3","title":"C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV","status":"RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-06-02","conditions":"HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection","enrollment":880},{"nctId":"NCT07314346","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone","status":"NOT_YET_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-12","conditions":"Healthy Volunteer Study","enrollment":32},{"nctId":"NCT07272889","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)","status":"NOT_YET_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-12","conditions":"Healthy Volunteer Study","enrollment":24},{"nctId":"NCT06868264","phase":"PHASE3","title":"C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-04-07","conditions":"HEPATITIS C VIRUS CHRONIC INFECTION","enrollment":880},{"nctId":"NCT05904470","phase":"PHASE2","title":"A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2023-05-30","conditions":"Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C","enrollment":275},{"nctId":"NCT06911320","phase":"PHASE1","title":"Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function","status":"RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-04-09","conditions":"Healthy Volunteer Study, Hepatic Impairment, Renal Impairment","enrollment":28},{"nctId":"NCT07007806","phase":"PHASE1","title":"Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-05-09","conditions":"Healthy Volunteer Study","enrollment":20},{"nctId":"NCT06921941","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-04-08","conditions":"Healthy Volunteer Study","enrollment":38},{"nctId":"NCT06204679","phase":"PHASE1","title":"Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2023-12-14","conditions":"Healthy Volunteer Study","enrollment":42},{"nctId":"NCT06356194","phase":"PHASE1","title":"Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2024-04-15","conditions":"Healthy Volunteer Study","enrollment":28},{"nctId":"NCT05731843","phase":"PHASE1","title":"Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2023-01-30","conditions":"Healthy Volunteer Study","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["(BEM/RZR)"],"phase":"phase_3","status":"active","brandName":"Bemnifosbuvir-Ruzasvir","genericName":"Bemnifosbuvir-Ruzasvir","companyName":"Atea Pharmaceuticals, Inc.","companyId":"atea-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bemnifosbuvir is a nucleoside analog that inhibits hepatitis C virus (HCV) RNA-dependent RNA polymerase, while ruzasvir is an NS5A inhibitor that blocks viral protein function and replication. Used for Chronic hepatitis C virus (HCV) infection, genotype 1-6.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}